SCHEMBL3008232

SCHEMBL3008232

COc1cccc(Cc2csc(N3CCN(S(=O)(=O)c4cccc(Br)c4)CC3)n2)c1

nearest known ligand 0.52

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAPT P10636 4/20 0.52
HSD17B10 Q99714 2/20 0.52
USP2 O75604 1/20 0.52
RECQL P46063 1/20 0.52
LMNA P02545 3/20 0.50
HTT P42858 1/20 0.50
TSHR P16473 2/20 0.47
ALOX15 P16050 1/20 0.47
MAPK1 P28482 1/20 0.45
KMT2A Q03164 3/20 0.44
MEN1 O00255 2/20 0.44
IDO1 P14902 1/20 0.44
GBA1 P04062 2/20 0.44
NPC1 O15118 1/20 0.43
APOBEC3A P31941 1/20 0.43
APOBEC3G Q9HC16 1/20 0.43
ALDH1A1 P00352 4/20 0.43
HPGD P15428 1/20 0.43
PKM P14618 2/20 0.42
POLB P06746 2/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3006874 0.94 USP2 (0.49) MAPTHSD17B10USP2RECQLLMNA
SCHEMBL3015344 0.94 MAPT (0.56) MAPTHSD17B10USP2RECQLLMNA
SCHEMBL3007682 0.92 LMNA (0.61) MAPTHSD17B10USP2RECQLLMNA
SCHEMBL3014551 0.92 MAPT (0.49) MAPTHSD17B10USP2RECQLLMNA
SCHEMBL3012672 0.91 KMT2A (0.50) MAPTHSD17B10USP2RECQLLMNA
SCHEMBL3015962 0.89 MAPT (0.52) MAPTHSD17B10USP2RECQLLMNA
SCHEMBL3002262 0.89 MAPT (0.59) MAPTHSD17B10USP2RECQLLMNA
SCHEMBL3017968 0.89 TSHR (0.48) MAPTHSD17B10USP2RECQLLMNA
SCHEMBL3007579 0.88 MEN1 (0.46) MAPTHSD17B10USP2RECQLLMNA
SCHEMBL3652063 0.88 MAPT (0.52) MAPTHSD17B10USP2RECQLLMNA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2188272-B1 PHENYL- AND BENZYLTHIAZOLYLPIPERAZINE DERIVATIVES FOR THE TREATMENT OF NEURODEGENERATIVE DISEASES REMYND NV (BE) 2016-02-24 EP disclosed
US-8722681-B2 N-sulfonyl thiazolylpiperazine derivatives and related N-sulfonyl heterocyclic derivatives for the treatment of neuro degenerative diseases NV REMYND (BE) 2014-05-13 US disclosed
US-20100197703-A1 N-SULFONYL THIAZOLYLPIPERAZINE DERIVATIVES AND RELATED N-SULFONYL HETEROCYCLIC DERIVATIVES FOR THE TREATMENT OF NEURO DEGENERATIVE DISEASES NV REMYND (BE) 2010-08-05 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100197703-A1 N-SULFONYL THIAZOLYLPIPERAZINE DERIVATIVES AND RELATED N-SULFONYL HETEROCYCLIC DERIVATIVES FOR THE TREATMENT OF NEURO DEGENERATIVE DISEASES SMN1; SMN2, HTT, SNCA MAPT 18/4885HSD17B10 2553/4885USP2 1831/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.